In response to COVID-19, DiaSys currently develops a serological assay to detect SARS-CoV-2 total antibodies. This test allows identification of individuals who have developed an immune response against the virus, even if they were asymptomatic or never have been diagnosed with the disease.
The SARS-CoV-2 UTAB FS assay is a particle enhanced immunoturbidimetric assays (PETIA) which enable a qualitative resp. semi-quantitative detection of total antibodies to SARS-CoV-2 in human serum and plasma. Since neutralizing antibodies directed against the spike protein can induce protective immunity against viral infection, the new DiaSys assay SARS-CoV-2 UTAB FS targets antibodies directed against the receptor binding domain (RBD) of the viral spike protein. This region is responsible for binding to the host cell receptor, allowing the virus to enter the host cell. The serological test offers high specificity and sensitivity and shows no cross-reactivity to the four human coronaviruses, which share partial sequence homology with SARS-CoV-2. Therefore, it reduces the risk of false positives due to the detection of similar antibodies that may be present. The innovative DiaSys reagent and the dedicated calibrators and controls will be available as liquid-stable products. The suffix UTAB - Universal Total Antibody - in the product name refers to the fact that this test can be applied on almost all clinical chemistry analyzers.
DiaSys is pleased to provide a rapid test for qualitative detection of specific antigens in COVID-19. The gold nanoparticle-based immunochromatographic test, SGTi-flex COVID-19 Ag, enables a qualitative determination from nasopharyngeal swab. It offers high sensitivity and specificity, and shows no cross-reactivity by other viruses or pathogens. The test delivers results within only 20 - 30 minutes. It does not require any additional materials or device, thereby, increasing the testing capacity, especially in countries that do not have extensive laboratory facilities for molecular testing (polymerase chain reaction or PCR).
With immediate effect, DiaSys offers a rapid test for the detection of IgM and IgG antibodies in COVID-19. The gold nanoparticle-based immunochromatographic test SGTi-flex COVID-19 IgM/IgG allows qualitative determination in whole blood (finger prick blood), serum und plasma. It exhibits high specificity and sensitivity, shows no cross-reactivity by other viruses or pathogens and delivers reliable results within 10 to 15 minutes. The new product will positively contribute to pandemic management because this test is fast, reduces workload on centralized testing laboratories and is the test of choice in resource-limited countries.
DiaSys is please to let you know, that we offer a rapid test for influenza A and/or B detection. SGTi-flex Influenza A&B test is a lateral flow immunochromatographic assay based on gold nanoparticles and allows a differential diagnosis of influenza A and/or B. Measurements are performed from samples of nasopharyngeal swab. Supported by high specificity and sensitivity, no cross-reactivity by other viruses or pathogens and ease of use, qualitative and reliable results are available after 3-10 minutes.
Laboratory medicine plays an important role in early detection, diagnosis and treatment of COVID-19. The IFCC has published an information guide on biochemical monitoring of COVID-19 patients. DiaSys offers a variety of reagents for parameters that are recommended for monitoring of the disease. For more information on DiaSys parameters in COVID-19 monitoring, please visit the attached pdfs where you can find summaries for each parameter.
Serum procalcitonin (PCT) levels are a sensitive marker for severe and systemic bacterial infections. PCT is primarily produced in thyroid C cells as a precursor of calcitonin but expressed in nearly all tissues by stimulation of interleukins and bacterial endotoxins. In healthy individuals, PCT concentrations are usually below 0.05 ng/mL, and a significant increase of PCT up to a thousand-fold appears within a few hours in patients with severe and systemic bacterial infections.
DiaSys Procalcitonin FS is a fluid-stable, particle enhanced immunoturbidimetric assay with outstanding onboard and calibration stability, providing a convenient workflow on clinical chemistry analyzers. Determinations of PCT in serum and plasma within the measuring range from 0.2 ng/mL to 50 ng/mL can be performed with high precision at clinical cut-off levels for sepsis. The performance is complemented by high tolerance to endogenous interferents and various therapeutics used in sepsis management. Procalcitonin FS shows a good correlation to established methods. Results from ring trials and a publication demonstrate the strengths of the assay.
respons®940 is a fully automatic random access analyzer (RAM) with a sample throughput of 400 (640 incl. ISE) tests/hour. Due to durable quartz cuvettes, low reaction volume, maintenance free photometer and intuitively operated software, respons®940 offers the economic use and reliability required in small to medium sized labs. In combination with DiaSys' high quality reagents perfectly matching to respons®940 highest results security and therefore a minimized number of reruns can be assured.
The accuracy and reliability of measurement results depend to a large extent on the quality of the process water used.
The DiaSys water purification systems O classic, O mini and O maxi work with coordinated cleaning steps to produce purest water of highest quality. The systems are designed to work perfectly with our analyzers. They produce from 15 L/h up to 55 L/h and have a water buffer tank from 9 L up to 75 L capacity. With these water treatment systems and together with our reagents and analytical instruments, DiaSys offers the complete package for reliable results.
In addition, the respons®920 and respons®940 analyzers offer the option of using an autofilling system to avoid the inconvenience of filling the deionized water tank. The autofilling system is installed directly in the deionized water tank and connected to the water purification system, eliminating the time needed to refill the water tank and eliminating the risk of the analyzer stopping due to lack of water. This makes your laboratory work even more efficient.
DiaSys – Choosing Quality. Also for laboratory water!
Increased serum bile acid levels are associated with several diseases such as acute and chronic hepatitis, intrahepatic cholestasis of pregnancy, liver sclerosis, cirrhosis, and cancer. Commercially available assays show limitations regarding the detection of clinically relevant primary and secondary bile acids. DiaSys introduces a liquid-stable, ready-to-use reagent with excellent recovery of diagnostically relevant bile acids (target deviation ≤ 7%). DiaSys Total bile acids 21 FS has a wide measuring range, good precision and long onboard and calibration stability. DiaSys provides a dedicated calibrator for optimum performance and multi-parameter controls for a convenient workflow.
Diabetic ketoacidosis is an acute, life-threatening complication which should be detected and treated immediately. Urine test strips that are commonly used for detection of ketoacidosis, are associated with several limitations. Since β-hydroxybutyrate levels increase more rapidly than levels of acetoacetate and acetone, serum/plasma β-hydroxybutyrate determination is a superior biomarker for ketoacidosis and recommended by the American Diabetes Association. Benefits are a minimized risk for false negative results, earlier identification and treatment through quantitative results and measurements that are less susceptible to drug interference.
With β-Hydroxybutyrate 21 FS, DiaSys offers a liquid-stable, ready-to-use reagent applicable to common clinical chemistry analyzers. The assay is suitable for serum and plasma samples, has a wide measuring range, excellent precision and superior calibration and onboard stability of up to 12 weeks. The test includes the DiaSys Lipid Clearing System, assuring correct results unaffected by lipid interference.
Diagnostic Reagents and System Solutions of Outstanding Quality!
DiaSys Diagnostic Systems is a leading specialist in development and manufacturing of diagnostic system solutions. Our goal is to combine high quality with ease of use and to reduce the environmental burden. Focusing on clinical chemistry and immunoturbidimetric tests, DiaSys has introduced more than 100 reagents in user-friendly kits for manual or automated use. DiaSys reagents ensure reliable results in routine and special diagnostics as e.g. diabetes, metabolic syndrome, lipid disorders, iron metabolism, pancreatic, kidney or liver diseases.
The instrumentation portfolio comprises automated clinical chemistry analyzers for small to medium sized laboratories (respons®910, respons®920, respons®940 and BioMajesty®JCA-BM 6010/C), semi-automated analyzers (StarDust MC15) and POCT instruments (InnovaStar® and SensoStar). Additionally, DiaSys offers a broad range of calibrators (TruCal) and quality control material (TruLab).
DiaSys continuously expands its reagent and system portfolio.
At the beginning of 2020, DiaSys launched a new sensitive marker for severe and systemic bacterial infections – Procalcitonin FS. DiaSys Procalcitonin FS is a fluid-stable, particle enhanced immunoturbidimetric assay with good precision at clinical cut-offs for sepsis. The assay has an outstanding onboard and calibration stability. The performance of Procalcitonin FS is comparable to established methods, presenting a reliable alternative for clinical chemistry analyzers.
DiaSys is an ISO certified company since 1996 (ISO 13485). To date, customers and partners in more than 100 countries rely on DiaSys’ quality.
Area of business